Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma
BACKGROUND Intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity. The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (youn...
Gespeichert in:
| Veröffentlicht in: | Cancer 2002-04, Vol.94 (7), p.1961-1967 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1967 |
|---|---|
| container_issue | 7 |
| container_start_page | 1961 |
| container_title | Cancer |
| container_volume | 94 |
| creator | Gronlund, Bo Høgdall, Claus Hansen, Heine H. Engelholm, Svend A. |
| description | BACKGROUND
Intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity. The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (younger than 65 years of age) patients receiving intravenous second‐line treatment of epithelial ovarian carcinoma.
METHODS
This study was a retrospective analysis of 286 consecutive patients with primary epithelial ovarian carcinoma. Inclusion criteria included histopathologically documented International Federation of Gynecology and Obstetrics (FIGO) Stage IC–IV epithelial ovarian carcinoma; first‐line treatment with paclitaxel and a platinum analog; intravenous second‐line treatment with topotecan 1.0 mg/m2/day for 5 days, every 3 weeks or paclitaxel (175 mg/m2) and carboplatin (AUC 5), every 3 weeks.
RESULTS
One hundred two patients fulfilled the inclusion criteria receiving topotecan (n = 57) or paclitaxel‐carboplatin (n = 45) because of refractory or recurrent disease. The patients' age at start of second‐line treatment in the younger (n = 68) and the elderly (n = 34) group were median 54.0 years (range, 34.7–64.3) and 69.5 years (range, 65.1–77.2), respectively. In the patient group aged younger than 65 years, initial performance status was more favorable than in patients aged older than 65 years (P = 0.007) whereas the groups were similar in relation to other potential prognostic factors (P > 0.05). For patients aged younger than 65 years, the overall response rate of 50% (95% confidence interval [CI], 37–63%) was similar to the response rate of 44% (95% CI, 27–62%) in patients aged older than 65 years (P = 0.29). The overall survival from the first day of second‐line treatment in patients aged younger and older than 65 years were median 13.3+ months (range, 1.2–38.3+) and 11.8+ months (range, 2.0–41.0+), respectively (P = 0.25). In a multivariate Cox analysis, performance status at time of first‐line treatment (0 vs.1–2; P = 0.013; hazard ratio [HR], 2.12), performance status at time of second‐line treatment (0 vs. 1–2; P = 0.004; HR, 2.47), and response to second‐line treatment (CR + PR vs. NC + PD; P < 0.001; HR, 4.38) were found to be independent significant factors for overall survival whereas age (younger than 65 years vs. older than 65 years) yielded no independent information (P = 0.90). No differences in the rate of postponement of treatment, neutro |
| doi_str_mv | 10.1002/cncr.10385 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_cncr_10385</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR10385</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3915-f30d47e894de4d65a6e20059a13aacec53e3b37b6023101ead629130cbe680e03</originalsourceid><addsrcrecordid>eNp9kMtKBDEQRYMoOj42foBk40ZorXT6uZTBF4iKKLhratLVTrQ7GZKMMjs_wW_0S4zOgDs3ya1wUhcOY_sCjgVAeqKMcjHJKl9jIwF1mYDI0nU2AoAqyTP5tMW2vX-JY5nmcpNtCVHLtKqrEfu8I9dZN6BRxH3AMPfcYZiS42GKhuMzce1jJv5KCz5z9tlYH7TiHapgHdeGe1LWtF8fn702xIMjDAOZwG3HqW_J9fEfBh2fPH_XYcppFk_qNfbcvqHTsUehU9rYAXfZRoe9p73VvcMez88expfJ9e3F1fj0OlGyFnnSSWizkqo6aylrixwLSgHyGoVEVKRySXIiy0kBqRQgCNsirYUENaGiAgK5w46We5Wz3jvqmpnTA7pFI6D50dr8aG1-tUb4YAnP5pOB2j905TEChysAvcK-c9Gn9n-czKtSijRyYsm9654W_1Q245vx_bL8G6mGk_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><source>Alma/SFX Local Collection</source><creator>Gronlund, Bo ; Høgdall, Claus ; Hansen, Heine H. ; Engelholm, Svend A.</creator><creatorcontrib>Gronlund, Bo ; Høgdall, Claus ; Hansen, Heine H. ; Engelholm, Svend A.</creatorcontrib><description>BACKGROUND
Intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity. The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (younger than 65 years of age) patients receiving intravenous second‐line treatment of epithelial ovarian carcinoma.
METHODS
This study was a retrospective analysis of 286 consecutive patients with primary epithelial ovarian carcinoma. Inclusion criteria included histopathologically documented International Federation of Gynecology and Obstetrics (FIGO) Stage IC–IV epithelial ovarian carcinoma; first‐line treatment with paclitaxel and a platinum analog; intravenous second‐line treatment with topotecan 1.0 mg/m2/day for 5 days, every 3 weeks or paclitaxel (175 mg/m2) and carboplatin (AUC 5), every 3 weeks.
RESULTS
One hundred two patients fulfilled the inclusion criteria receiving topotecan (n = 57) or paclitaxel‐carboplatin (n = 45) because of refractory or recurrent disease. The patients' age at start of second‐line treatment in the younger (n = 68) and the elderly (n = 34) group were median 54.0 years (range, 34.7–64.3) and 69.5 years (range, 65.1–77.2), respectively. In the patient group aged younger than 65 years, initial performance status was more favorable than in patients aged older than 65 years (P = 0.007) whereas the groups were similar in relation to other potential prognostic factors (P > 0.05). For patients aged younger than 65 years, the overall response rate of 50% (95% confidence interval [CI], 37–63%) was similar to the response rate of 44% (95% CI, 27–62%) in patients aged older than 65 years (P = 0.29). The overall survival from the first day of second‐line treatment in patients aged younger and older than 65 years were median 13.3+ months (range, 1.2–38.3+) and 11.8+ months (range, 2.0–41.0+), respectively (P = 0.25). In a multivariate Cox analysis, performance status at time of first‐line treatment (0 vs.1–2; P = 0.013; hazard ratio [HR], 2.12), performance status at time of second‐line treatment (0 vs. 1–2; P = 0.004; HR, 2.47), and response to second‐line treatment (CR + PR vs. NC + PD; P < 0.001; HR, 4.38) were found to be independent significant factors for overall survival whereas age (younger than 65 years vs. older than 65 years) yielded no independent information (P = 0.90). No differences in the rate of postponement of treatment, neutropenia Grade 4, trombocytopenia Grade 3–4, nor hypersensitivity reaction to either cytostatic agent between older and younger patients were noticed (P > 0.05).
CONCLUSIONS
Modality of second‐line treatment of epithelial ovarian carcinoma should be determined more by assessment of performance status than age per se. Second‐line treatment with topotecan or paclitaxel‐carboplatin can be safely administered in the aged. Cancer 2002;94:1961–7. © 2002 American Cancer Society.
DOI 10.1002/cncr.10385
Newer intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma are withheld from many elderly patients because of fear of toxicity. In a retrospective analysis of 102 patients receiving intravenous second‐line treatment with topotecan or paclitaxel‐carboplatin, no differences in overall survival or overall response rates nor number of toxicity events between comparable groups of older (older than 65 years) and younger (younger than 65 years) patients were noticed (P > 0.05). Modern intravenous cytostatics in second‐line treatment can be safely administered in the aged.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.10385</identifier><identifier>PMID: 11932898</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Age Factors ; Aged ; Aging - physiology ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; carboplatin ; Carboplatin - administration & dosage ; Carboplatin - adverse effects ; Chemotherapy ; elderly ; Epithelial Cells - pathology ; epithelial ovarian carcinoma ; Female ; Humans ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - mortality ; overall survival ; paclitaxel ; Paclitaxel - administration & dosage ; Paclitaxel - adverse effects ; Pharmacology. Drug treatments ; progression free survival ; recurrence ; Retrospective Studies ; second‐line treatment ; Survival Rate ; topotecan ; Topotecan - administration & dosage ; Topotecan - adverse effects</subject><ispartof>Cancer, 2002-04, Vol.94 (7), p.1961-1967</ispartof><rights>Copyright © 2002 American Cancer Society</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3915-f30d47e894de4d65a6e20059a13aacec53e3b37b6023101ead629130cbe680e03</citedby><cites>FETCH-LOGICAL-c3915-f30d47e894de4d65a6e20059a13aacec53e3b37b6023101ead629130cbe680e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.10385$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.10385$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13587312$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11932898$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gronlund, Bo</creatorcontrib><creatorcontrib>Høgdall, Claus</creatorcontrib><creatorcontrib>Hansen, Heine H.</creatorcontrib><creatorcontrib>Engelholm, Svend A.</creatorcontrib><title>Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
Intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity. The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (younger than 65 years of age) patients receiving intravenous second‐line treatment of epithelial ovarian carcinoma.
METHODS
This study was a retrospective analysis of 286 consecutive patients with primary epithelial ovarian carcinoma. Inclusion criteria included histopathologically documented International Federation of Gynecology and Obstetrics (FIGO) Stage IC–IV epithelial ovarian carcinoma; first‐line treatment with paclitaxel and a platinum analog; intravenous second‐line treatment with topotecan 1.0 mg/m2/day for 5 days, every 3 weeks or paclitaxel (175 mg/m2) and carboplatin (AUC 5), every 3 weeks.
RESULTS
One hundred two patients fulfilled the inclusion criteria receiving topotecan (n = 57) or paclitaxel‐carboplatin (n = 45) because of refractory or recurrent disease. The patients' age at start of second‐line treatment in the younger (n = 68) and the elderly (n = 34) group were median 54.0 years (range, 34.7–64.3) and 69.5 years (range, 65.1–77.2), respectively. In the patient group aged younger than 65 years, initial performance status was more favorable than in patients aged older than 65 years (P = 0.007) whereas the groups were similar in relation to other potential prognostic factors (P > 0.05). For patients aged younger than 65 years, the overall response rate of 50% (95% confidence interval [CI], 37–63%) was similar to the response rate of 44% (95% CI, 27–62%) in patients aged older than 65 years (P = 0.29). The overall survival from the first day of second‐line treatment in patients aged younger and older than 65 years were median 13.3+ months (range, 1.2–38.3+) and 11.8+ months (range, 2.0–41.0+), respectively (P = 0.25). In a multivariate Cox analysis, performance status at time of first‐line treatment (0 vs.1–2; P = 0.013; hazard ratio [HR], 2.12), performance status at time of second‐line treatment (0 vs. 1–2; P = 0.004; HR, 2.47), and response to second‐line treatment (CR + PR vs. NC + PD; P < 0.001; HR, 4.38) were found to be independent significant factors for overall survival whereas age (younger than 65 years vs. older than 65 years) yielded no independent information (P = 0.90). No differences in the rate of postponement of treatment, neutropenia Grade 4, trombocytopenia Grade 3–4, nor hypersensitivity reaction to either cytostatic agent between older and younger patients were noticed (P > 0.05).
CONCLUSIONS
Modality of second‐line treatment of epithelial ovarian carcinoma should be determined more by assessment of performance status than age per se. Second‐line treatment with topotecan or paclitaxel‐carboplatin can be safely administered in the aged. Cancer 2002;94:1961–7. © 2002 American Cancer Society.
DOI 10.1002/cncr.10385
Newer intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma are withheld from many elderly patients because of fear of toxicity. In a retrospective analysis of 102 patients receiving intravenous second‐line treatment with topotecan or paclitaxel‐carboplatin, no differences in overall survival or overall response rates nor number of toxicity events between comparable groups of older (older than 65 years) and younger (younger than 65 years) patients were noticed (P > 0.05). Modern intravenous cytostatics in second‐line treatment can be safely administered in the aged.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Aging - physiology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>carboplatin</subject><subject>Carboplatin - administration & dosage</subject><subject>Carboplatin - adverse effects</subject><subject>Chemotherapy</subject><subject>elderly</subject><subject>Epithelial Cells - pathology</subject><subject>epithelial ovarian carcinoma</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - mortality</subject><subject>overall survival</subject><subject>paclitaxel</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - adverse effects</subject><subject>Pharmacology. Drug treatments</subject><subject>progression free survival</subject><subject>recurrence</subject><subject>Retrospective Studies</subject><subject>second‐line treatment</subject><subject>Survival Rate</subject><subject>topotecan</subject><subject>Topotecan - administration & dosage</subject><subject>Topotecan - adverse effects</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKBDEQRYMoOj42foBk40ZorXT6uZTBF4iKKLhratLVTrQ7GZKMMjs_wW_0S4zOgDs3ya1wUhcOY_sCjgVAeqKMcjHJKl9jIwF1mYDI0nU2AoAqyTP5tMW2vX-JY5nmcpNtCVHLtKqrEfu8I9dZN6BRxH3AMPfcYZiS42GKhuMzce1jJv5KCz5z9tlYH7TiHapgHdeGe1LWtF8fn702xIMjDAOZwG3HqW_J9fEfBh2fPH_XYcppFk_qNfbcvqHTsUehU9rYAXfZRoe9p73VvcMez88expfJ9e3F1fj0OlGyFnnSSWizkqo6aylrixwLSgHyGoVEVKRySXIiy0kBqRQgCNsirYUENaGiAgK5w46We5Wz3jvqmpnTA7pFI6D50dr8aG1-tUb4YAnP5pOB2j905TEChysAvcK-c9Gn9n-czKtSijRyYsm9654W_1Q245vx_bL8G6mGk_w</recordid><startdate>20020401</startdate><enddate>20020401</enddate><creator>Gronlund, Bo</creator><creator>Høgdall, Claus</creator><creator>Hansen, Heine H.</creator><creator>Engelholm, Svend A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20020401</creationdate><title>Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma</title><author>Gronlund, Bo ; Høgdall, Claus ; Hansen, Heine H. ; Engelholm, Svend A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3915-f30d47e894de4d65a6e20059a13aacec53e3b37b6023101ead629130cbe680e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Aging - physiology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>carboplatin</topic><topic>Carboplatin - administration & dosage</topic><topic>Carboplatin - adverse effects</topic><topic>Chemotherapy</topic><topic>elderly</topic><topic>Epithelial Cells - pathology</topic><topic>epithelial ovarian carcinoma</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - mortality</topic><topic>overall survival</topic><topic>paclitaxel</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - adverse effects</topic><topic>Pharmacology. Drug treatments</topic><topic>progression free survival</topic><topic>recurrence</topic><topic>Retrospective Studies</topic><topic>second‐line treatment</topic><topic>Survival Rate</topic><topic>topotecan</topic><topic>Topotecan - administration & dosage</topic><topic>Topotecan - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gronlund, Bo</creatorcontrib><creatorcontrib>Høgdall, Claus</creatorcontrib><creatorcontrib>Hansen, Heine H.</creatorcontrib><creatorcontrib>Engelholm, Svend A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gronlund, Bo</au><au>Høgdall, Claus</au><au>Hansen, Heine H.</au><au>Engelholm, Svend A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2002-04-01</date><risdate>2002</risdate><volume>94</volume><issue>7</issue><spage>1961</spage><epage>1967</epage><pages>1961-1967</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
Intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity. The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (younger than 65 years of age) patients receiving intravenous second‐line treatment of epithelial ovarian carcinoma.
METHODS
This study was a retrospective analysis of 286 consecutive patients with primary epithelial ovarian carcinoma. Inclusion criteria included histopathologically documented International Federation of Gynecology and Obstetrics (FIGO) Stage IC–IV epithelial ovarian carcinoma; first‐line treatment with paclitaxel and a platinum analog; intravenous second‐line treatment with topotecan 1.0 mg/m2/day for 5 days, every 3 weeks or paclitaxel (175 mg/m2) and carboplatin (AUC 5), every 3 weeks.
RESULTS
One hundred two patients fulfilled the inclusion criteria receiving topotecan (n = 57) or paclitaxel‐carboplatin (n = 45) because of refractory or recurrent disease. The patients' age at start of second‐line treatment in the younger (n = 68) and the elderly (n = 34) group were median 54.0 years (range, 34.7–64.3) and 69.5 years (range, 65.1–77.2), respectively. In the patient group aged younger than 65 years, initial performance status was more favorable than in patients aged older than 65 years (P = 0.007) whereas the groups were similar in relation to other potential prognostic factors (P > 0.05). For patients aged younger than 65 years, the overall response rate of 50% (95% confidence interval [CI], 37–63%) was similar to the response rate of 44% (95% CI, 27–62%) in patients aged older than 65 years (P = 0.29). The overall survival from the first day of second‐line treatment in patients aged younger and older than 65 years were median 13.3+ months (range, 1.2–38.3+) and 11.8+ months (range, 2.0–41.0+), respectively (P = 0.25). In a multivariate Cox analysis, performance status at time of first‐line treatment (0 vs.1–2; P = 0.013; hazard ratio [HR], 2.12), performance status at time of second‐line treatment (0 vs. 1–2; P = 0.004; HR, 2.47), and response to second‐line treatment (CR + PR vs. NC + PD; P < 0.001; HR, 4.38) were found to be independent significant factors for overall survival whereas age (younger than 65 years vs. older than 65 years) yielded no independent information (P = 0.90). No differences in the rate of postponement of treatment, neutropenia Grade 4, trombocytopenia Grade 3–4, nor hypersensitivity reaction to either cytostatic agent between older and younger patients were noticed (P > 0.05).
CONCLUSIONS
Modality of second‐line treatment of epithelial ovarian carcinoma should be determined more by assessment of performance status than age per se. Second‐line treatment with topotecan or paclitaxel‐carboplatin can be safely administered in the aged. Cancer 2002;94:1961–7. © 2002 American Cancer Society.
DOI 10.1002/cncr.10385
Newer intravenous cytostatic agents as second‐line treatment of epithelial ovarian carcinoma are withheld from many elderly patients because of fear of toxicity. In a retrospective analysis of 102 patients receiving intravenous second‐line treatment with topotecan or paclitaxel‐carboplatin, no differences in overall survival or overall response rates nor number of toxicity events between comparable groups of older (older than 65 years) and younger (younger than 65 years) patients were noticed (P > 0.05). Modern intravenous cytostatics in second‐line treatment can be safely administered in the aged.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>11932898</pmid><doi>10.1002/cncr.10385</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2002-04, Vol.94 (7), p.1961-1967 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_cncr_10385 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Wiley Online Library All Journals; Alma/SFX Local Collection |
| subjects | Age Factors Aged Aging - physiology Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences carboplatin Carboplatin - administration & dosage Carboplatin - adverse effects Chemotherapy elderly Epithelial Cells - pathology epithelial ovarian carcinoma Female Humans Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality overall survival paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Pharmacology. Drug treatments progression free survival recurrence Retrospective Studies second‐line treatment Survival Rate topotecan Topotecan - administration & dosage Topotecan - adverse effects |
| title | Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A11%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Performance%20status%20rather%20than%20age%20is%20the%20key%20prognostic%20factor%20in%20second%E2%80%90line%20treatment%20of%20elderly%20patients%20with%20epithelial%20ovarian%20carcinoma&rft.jtitle=Cancer&rft.au=Gronlund,%20Bo&rft.date=2002-04-01&rft.volume=94&rft.issue=7&rft.spage=1961&rft.epage=1967&rft.pages=1961-1967&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.10385&rft_dat=%3Cwiley_cross%3ECNCR10385%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11932898&rfr_iscdi=true |